These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8822446)

  • 1. Total ovarian volume before human chorionic gonadotrophin administration for ovulation induction may predict the hyperstimulation syndrome.
    Oyesanya OA; Parsons JH; Collins WP; Campbell S
    Hum Reprod; 1995 Dec; 10(12):3211-12. PubMed ID: 8822446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?
    Lee C; Tummon I; Martin J; Nisker J; Power S; Tekpetey F
    Hum Reprod; 1998 May; 13(5):1157-8. PubMed ID: 9647538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
    PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization.
    Zhu WJ; Li XM; Chen XM; Zhang L
    Eur J Obstet Gynecol Reprod Biol; 2005 Sep; 122(1):79-84. PubMed ID: 16154042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrafollicular hemodynamics before the administration of human chorionic gonadotropin in women at risk of the ovarian hyperstimulation syndrome.
    Oyesanya OA; Parsons JH; Collins WP; Campbell S
    Fertil Steril; 1996 Apr; 65(4):874-6. PubMed ID: 8654656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified 'coasting' strategy based on ultrasound for identification of high-risk patients.
    Al-Shawaf T; Zosmer A; Hussain S; Tozer A; Panay N; Wilson C; Lower AM; Grudzinskas JG
    Hum Reprod; 2001 Jan; 16(1):24-30. PubMed ID: 11139531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment.
    Abbara A; Islam R; Clarke SA; Jeffers L; Christopoulos G; Comninos AN; Salim R; Lavery SA; Vuong TNL; Humaidan P; Kelsey TW; Trew GH; Dhillo WS
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):920-927. PubMed ID: 29446481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe ovarian hyperstimulation syndrome following salvage of empty follicle syndrome.
    Evbuomwan IO; Fenwick JD; Shiels R; Herbert M; Murdoch AP
    Hum Reprod; 1999 Jul; 14(7):1707-9. PubMed ID: 10402372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization.
    Sher G; Zouves C; Feinman M; Maassarani G
    Hum Reprod; 1995 Dec; 10(12):3107-9. PubMed ID: 8822423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of severe ovarian hyperstimulation syndrome (OHSS) in IVF patients by steroidal ovarian suppression--a prospective randomized study.
    Schwärzler P; Abendstein BJ; Klingler A; Kreuzer E; Rjosk HK
    Hum Fertil (Camb); 2003 Aug; 6(3):125-9. PubMed ID: 12960445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro fertilization and the ovarian hyperstimulation syndrome.
    MacDougall MJ; Tan SL; Jacobs HS
    Hum Reprod; 1992 May; 7(5):597-600. PubMed ID: 1639974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.